Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 17/20 | 0.59 |
| ▸ | JAK2 | O60674 | 2/20 | 0.59 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.51 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633450 | 0.85 | LRRK2 (0.53) | LRRK2JAK2MAPK10MAP3K9MKNK2 | |
| SCHEMBL1867996 | 0.84 | LRRK2 (0.57) | LRRK2JAK2MAPK10MAP3K9MKNK2 | |
| SCHEMBL1633842 | 0.83 | LRRK2 (0.54) | LRRK2JAK2MAP3K9MKNK2PTK2 | |
| SCHEMBL14258582 | 0.83 | LRRK2 (0.51) | LRRK2JAK2MAPK10MAP3K9MKNK2 | |
| SCHEMBL14146487 | 0.81 | LRRK2 (0.57) | LRRK2JAK2MAPK10MAP3K9MKNK2 | |
| SCHEMBL12725748 | 0.80 | LRRK2 (0.64) | LRRK2JAK2MAPK10MAP3K9MKNK2 | |
| SCHEMBL1869925 | 0.77 | LRRK2 (0.54) | LRRK2JAK2MAPK10MAP3K9MKNK2 | |
| SCHEMBL12765003 | 0.77 | MAPK10 (0.53) | LRRK2JAK2MAPK10 | |
| SCHEMBL12724719 | 0.76 | LRRK2 (0.54) | LRRK2JAK2MAPK10MAP3K9MKNK2 | |
| SCHEMBL3465267 | 0.75 | PTK2 (0.39) | LRRK2JAK2MAPK10MKNK2PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | LRRK2 454/4885JAK2 1352/4885MAPK10 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.